Filter your results
- 3
- 1
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 3
- 1
- 1
- 1
- 4
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
A randomised, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).Clinical and Experimental Allergy, In press, ⟨10.1111/cea.13731⟩
Journal articles
hal-02936982v1
|
||
|
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaNew England Journal of Medicine, 2021, 384 (19), pp.1800-1809. ⟨10.1056/NEJMoa2034975⟩
Journal articles
hal-03225867v1
|
||
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyThe Lancet Respiratory Medicine, 2023, ⟨10.1016/S2213-2600(22)00492-1⟩
Journal articles
hal-03960913v1
|
|||
|
Extracellular DNA, Neutrophil Extracellular Traps, and Inflammasome Activation in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2019, 199 (9), pp.1076-1085. ⟨10.1164/rccm.201810-1869OC⟩
Journal articles
hal-02997946v1
|